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A novel application of gallium nitrate, hitherto unreported, in reducing bleeding time from an open wound is presented.
Experiments performed using simple punctures in the forearm demonstrated a very substantial reduction in bleeding
time when a solution of gallium nitrate was applied relative to a control. This outcome was shown to be unaﬀected
by the anticoagulant properties of warfarin. The mechanism for such action of gallium nitrate is unknown and merits
further investigation, as do the possibilities for such an application to improve both civilian and defense trauma treatment
modalities.
1.Introduction
Gallium nitrate, the gallium salt of nitric acid, is a drug
predominantly used to treat symptomatic hypercalcemia
secondarytocancer[1].Thepostulatedmechanism ofaction
is that it prevents the breakdown of bone through the
inhibition of osteoclast activity, thus lowering the amount
of free calcium in the blood [2]. It has been shown to be
more eﬀective than several other antihypercalcemic drugs
[3, 4]. Gallium nitrate has also been used in the treatment
of non-Hodgkin’s lymphoma [5, 6], multiple myeloma [7],
and Paget’s disease of bone [8]. To the best ofourknowledge,
no eﬀect of gallium on coagulation parameters has everbeen
reported to date.
Here we present a novel action of gallium nitrate, that of
stemming blood ﬂow from an open wound via a mechanism
of action as yet undetermined. After the serendipitous
discovery of the blood-ﬂow arresting properties of gallium
nitrate by one of our authors, the authors conducted an
experiment on themselves to explore this discovery further
and so determine the beneﬁt of gallium in stopping the
bleeding from wounds.
2.Case Presentation
This study was conducted on two subjects: one (Subject 1,
S1) under the inﬂuence of warfarin and one not under the
inﬂuence of warfarin (Subject 2, S2). Subject 1 was on long-
term warfarin treatment at the time of the experiment; this
was not expected to have a signiﬁcant eﬀect on primary
hemostasis.
Inbothcases, apunctureofthemedial mid-forearmwith
a number 11 scalpel blade to a depth of 4mm was made
(P1),producingpromptﬂowofbloodasasteadyslowstream
downtheforearm. Thiswasgentlywipedwith gauzeevery30
seconds without applying pressure. The time for bleeding to
stop was noted.
A second puncture (P2) was then made following the
same method as for the ﬁrst puncture. At 5 seconds after2 Case Reports in Medicine
Table 1: The eﬀect of gallium nitrate in reducing bleeding times from simple punctures (P1 and P2) in both warfarin- and nonwarfarin-
treated subjects (S1 and S2), with observations.
Subject Time for bleeding to stop (s) Reduction in bleeding time (%) Observations of P2
P1 (control) P2 (gallium nitrate)
S1 (warfarin) 122 35 71% Small pool of blood stayed about the incisionsite.
S2 (nonwarfarin) 238 45 81% Visible clot started to form once ﬂow had ceased.
puncture,oncebloodﬂowhadcommenced,aqueousgallium
nitrate (14%) solution (Eby Pharma LLC, Dripping Springs,
TX 78620) was applied using a soaked cotton ball. The time
for bleeding to stop was again noted.
3.Results
The times after which blood ﬂow ceased for each subject
and each puncture are noted in Table 1, along with pertinent
observations of the presence or absence of clotting.
4.Discussion
In this experiment, gallium nitrate substantially reduced
bleeding time from an open wound in both a warfarin-
treated subject (S1) and nonwarfarin-treated subject (S2)
when compared to the control (a reduction in bleeding time
from 122s to 35s for S1 versus 238s to 45s for S2). In this
experiment, warfarin did not negate or interfere with the
blood-stemming property of gallium nitrate. Interestingly,
whilst gallium nitrate stemmed the ﬂow of blood in both
subjects, the warfarin-treated subject did not form a visible
clot, whilst the nonwarfarin-treated subject formed a very
visible brown clot.
The eﬀect of gallium nitrate described herein requires
further investigation and veriﬁcation as part of a larger,
randomized control study, particularly with regards to its
mechanism of action (in particular, future experiments
should use a standardized bleeding time method such as the
Ivy Method or the Simplate II).
Gallium nitrate has known toxicities when used at
higherdosagesintravenously,especially overthelongerterm.
Infusion at a rate of around 300mg/m3/d causes renal
toxicity and/or diarrhoea in around 15% of patients studied
[2]. Microcytic anemia is a possibility, but no suppression of
p l a t e l e t so rW B C si ss e e n ;v i s u a lo ra u d i t o r yt o x i c i t i e so c c u r
very rarely. However, this present application of gallium
nitrate is a single, topical treatment with limited absorption.
While questions of toxicity should be addressed in further
trials,sideeﬀectscomparablewithintravenoususeofgallium
nitrate are not expected.
The discovery described in this paper would be of
particular relevance to the ﬁelds of emergency and defense
trauma treatment. One of the current most eﬀective treat-
ments for wounds in these situations is the application
of a kaolin-treated gauze (e.g., in the commercial product
QuikClot Combat Gauze [9, 10]), which is known to induce
coagulation [11, 12] by activation of Factor XII [13]. It may
be that gallium nitrate interacts with coagulation factors in a
manner similar to current commercial products; it would be
important to examine whether this eﬀect takes place only on
open wounds or whether gallium nitrate also has an internal
procoagulant eﬀect, which would necessitate consideration
when it is used as a therapeutic medicine.
This behavior of gallium nitrate would be a valuable
addition to such kaolin-based products, as while their usage
leadstohighsurvivalrates,theydonotnecessarilystopblood
ﬂow rapidly [10]. The possibilities for the use of gallium
nitrate in such situations merit further exploration.
5.Conclusions
Thispaperhasdemonstratedthehithertounknown abilityof
galliumnitratetoreducebleedingtimefromanopenwound.
The experiments performed in this case study indicate that
gallium nitrate can substantially reduce the blood ﬂow time
for simple puncturesrelative to a control. The mechanism by
which this occurs is unknown, although this eﬀect was not
interfered with by the anticoagulant properties of warfarin.
This eﬀectshould be further explored, both to determine
its mechanism of action and to exploit this property for
improved management oftrauma in bothcivilian emergency
and defense medical situations.
Conﬂictof Interests
One of the authors (M. Rogosnitzky) has a pending patent
application on the described use of gallium nitrate.
Acknowledgment
The authors acknowledge with gratitude the professional
assistance of Daniel Holt.
References
[1] F. Cvitkovic, J. P. Armand, M. Tubiana-Hulin, J. F. Rossi, and
R. P. Warrell Jr., “Randomized, double-blind, phase II trial of
gallium nitrate compared with pamidronate for acute control
of cancer-related hypercalcemia,” Cancer Journal, vol. 12, no.
1, pp. 47–53, 2006.
[2] C. J. Chitambar, “Medical applications and toxicities of
gallium compounds,” International Journal of Environmental
Research and Public Health, vol. 7, no. 5, pp. 2337–2361, 2010.
[ 3 ]R .P .W a r r e l lJ r . ,R .I s r a e l ,M .F r i s o n e ,T .S n y d e r ,J .J .G a y n o r ,
and R. S. Bockman, “Gallium nitrate for acute treatment
of cancer-related hypercalcemia: a randomized, double-blind
comparison to calcitonin,” Annals of Internal Medicine,v o l .
108, no. 5, pp. 669–674, 1988.
[ 4 ]R .P .W a r r e l lJ r . ,W .K .M u r p h y ,P .S c h u l m a n ,P .J .O ’ D w y e r ,
and G. Heller, “A randomized double-blind study of galliumCase Reports in Medicine 3
nitrate compared with etidronate for acute control of cancer-
related hypercalcemia,” Journal of Clinical Oncology,v o l .9 ,n o .
8, pp. 1467–1475, 1991.
[ 5 ]J .K .W e i c k ,R .L .S t e p h e n s ,L .H .B a k e r ,a n dS .E .J o n e s ,“ G a l -
lium nitrate in malignant lymphoma: a Southwest Oncology
Group study,” Cancer Treatment Reports,v o l .6 7 ,n o .9 ,p p .
823–825, 1983.
[6] D. J. Straus, “Gallium nitrate in the treatment of lymphoma,”
Seminars in Oncology, vol. 30, no. 2, pp. 25–33, 2003.
[7] R. P. Warrell Jr., D. Lovett, F. A. Dilmanian, R. Schneider,
and R. T. Heelan, “Low-dose gallium nitrate for prevention
of osteolysis in myeloma: results of a pilot randomized study,”
Journal of Clinical Oncology, vol. 11, no. 12, pp. 2443–2450,
1993.
[8] R. S. Bookman, F. Wilhelm, E. Siris et al., “A multicenter
trial of low dose gallium nitrate in patients with advanced
Paget’s disease of bone,” Journal of Clinical Endocrinology and
Metabolism, vol. 80, no. 2, pp. 595–602, 1995.
[9] M. Pahari, R. Moliver, D. Lo, and G. Basadonna, Pre-
sentation Poster, 2010, http://www.z-medica.com/ZMedica
/media/photos/posters/2010-02.ASDIN-2010.pdf.
[10] A Combat Medical SystemsTM (Fayetteville NC, USA) prod-
uct, 2010, http://www.combatmedicalsystems.com/Products
/List/1/CategoryID/1/Level/1.aspx.
[11] J. Margolis, “Activation of plasma by contact with glass:
evidence for a common reaction which releases plasma kinin
and initiates coagulation,” The Journal of Physiology, vol. 144,
no. 1, pp. 1–22, 1958.
[12] J. Margolis, “The kaolin clotting time; a rapid one-stage
method for diagnosis of coagulation defects,” Journal of
Clinical Pathology, vol. 11, no. 5, pp. 406–409, 1958.
[13] J. H. Griﬃn, “Role of surface in surface-dependent activation
of Hageman factor (blood coagulation Factor XII),” Proceed-
ings of the National Academy of Sciences of the United States of
America, vol. 75, no. 4, pp. 1998–2002, 1978.